# Hyperviscosity Syndrome

Treat symptomatic hyperviscosity as an oncologic emergency: recognize retinal, mucosal bleeding, neurologic, and cardiopulmonary injury; obtain viscosity and cause-directed studies without delaying plasma exchange; then suppress the responsible paraprotein-producing or leukemic process.

**Clinical question:** How should physicians identify, stabilize, and definitively manage symptomatic hyperviscosity syndrome?

Updated: 2026-08-24T18:15:13.028633+00:00

## What matters in practice
- New mucosal bleeding, visual disturbance, or neurologic dysfunction in a patient with suspected or known paraproteinemia warrants urgent evaluation for symptomatic hyperviscosity and should not await a viscosity result before therapeutic plasma exchange. [3][18][24]
- Serum viscosity above 4 relative to water is commonly associated with symptomatic hyperviscosity, but individual symptom thresholds vary and retinal disease may occur at lower serum viscosity or IgM levels. [1][7][8]
- Waldenstrom macroglobulinemia is the predominant paraprotein-associated cause; symptomatic hyperviscosity is less common in IgG- or IgA-associated myeloma. [16][18][23]
- Therapeutic plasma exchange rapidly removes circulating paraprotein but does not control the clone; start disease-directed cytoreduction concurrently to prevent recurrence. [18][23]
- Separate paraprotein hyperviscosity from leukostasis: symptomatic hyperleukocytosis requires immediate cytoreduction, isotonic fluids, and avoidance of nonessential red-cell transfusion while the leukocyte count remains high. [17][19][23]

## When to treat as hyperviscosity syndrome

Act on a compatible clinical syndrome rather than a laboratory value alone.

Hospitalize patients with a compatible syndrome and immediately involve hematology plus an apheresis-capable center. The classic high-risk pattern is mucosal bleeding, retinal or visual symptoms, and neurologic dysfunction; reported manifestations also include blurred vision, retinal hemorrhage, headache, vertigo, hearing change, ataxia, confusion, seizures, somnolence, coma, dyspnea, and heart failure. [3][16][23][24]

Obtain serum viscosity before exchange when doing so does not delay treatment, but do not use one numeric threshold to exclude symptomatic disease. Relative serum viscosity is normally about 1.4 to 1.8 times water; symptoms often emerge around 4 to 7, and a value greater than 4 is commonly associated with hyperviscosity syndrome. Clinical thresholds vary substantially, particularly with coexisting retinal disease, and Waldenstrom-related retinopathy can occur at lower serum IgM and viscosity levels than historically expected. [1][7][8]

Perform urgent funduscopic examination when visual complaints, headache, or bleeding accompany a suspected paraproteinemia. Retinal venous congestion, hemorrhages around small retinal vessels, papilledema, and segmented “sausage-like” venous changes support impaired retinal microcirculation and provide a bedside marker of response to plasma exchange. [16][18]
- Escalate immediately for declining consciousness, focal neurologic deficits, seizure, rapidly worsening vision, major bleeding, hypoxemia, or acute heart failure; these findings represent threatened end-organ perfusion or capillary injury. [16][20][24]
- Give crystalloid promptly if dehydration is present or suspected because dehydration worsens hyperviscosity. [23]
- Do not defer therapy for a high IgM or serum viscosity value in an otherwise asymptomatic patient; hyperviscosity syndrome is the clinical manifestation of increased viscosity, and symptom correlation is imperfect. [1][12][16]

*Syndrome features that should trigger urgent serum viscosity testing and apheresis planning. [3][16][18][24]*

| Organ system | Actionable findings | Immediate implication |
| --- | --- | --- |
| Eye | Blurred vision, visual loss, retinal hemorrhage, venous congestion, papilledema [3][16][18] | Urgent fundus examination; organize plasma exchange when findings are compatible with symptomatic hyperviscosity. [18] |
| Neurologic | Headache, vertigo, ataxia, diplopia, confusion, seizure, somnolence, coma [16][24] | Treat as a microcirculatory emergency while assessing alternate neurologic diagnoses. [16][20][24] |
| Bleeding | Epistaxis or other mucous-membrane bleeding [3][24] | Assess for paraproteinemia and urgent plasma exchange indication. [3][18] |
| Cardiopulmonary | Dyspnea or heart failure [16][24] | Assess volume status and end-organ compromise; avoid worsening dehydration while arranging definitive therapy. [23][24] |

## Identify whether viscosity is driven by paraprotein, cells, or cryoprotein

The cause determines the apheresis target and definitive treatment pathway.

For suspected serum hyperviscosity, send serum viscosity, serum protein studies to identify a monoclonal immunoglobulin, complete blood count, and basic organ assessment while arranging treatment for symptomatic patients. Markedly elevated Westergren erythrocyte sedimentation rate and increased serum immunoglobulins are supportive clues, but neither substitutes for serum viscosity or clinical assessment. [1][22]

Waldenstrom macroglobulinemia is the most frequent plasma-cell-dyscrasia context for symptomatic hyperviscosity because IgM overproduction promotes erythrocyte aggregation and impaired microvascular flow. Hyperviscosity occurs more often in Waldenstrom macroglobulinemia, reported at 10% to 30%, than in IgG- or IgA-associated myeloma, reported at 2% to 6%. [16][18][23]

Multiple myeloma remains an important alternative when a monoclonal protein accompanies anemia, marrow failure, kidney injury, or bone disease. Hyperviscosity is uncommon in myeloma but can cause epistaxis, blurred vision, retinal hemorrhage, neurologic symptoms, dyspnea, and heart failure; treat symptomatic cases as an emergency with immediate plasmapheresis. [10][24]

When serum becomes visibly gel-like on cooling and reversibly liquefies with warming, consider cryoglobulinemia as the cause of hyperviscosity. In this branch, rapidly evolving life-threatening disease is an indication for plasmapheresis, while the underlying cryoglobulinemic process requires cause-directed management. [5][18]

Do not conflate paraprotein hyperviscosity with leukostasis. Leukostasis is symptomatic hyperleukocytosis with neurologic and/or pulmonary manifestations; hyperleukocytosis is generally defined as a white blood cell count greater than 100,000 cells/μL. Whole-blood rather than serum viscosity is relevant when cellular burden is suspected, and acute leukemia requires immediate cytoreductive management. [17][19][22]
- In a patient with suspected Waldenstrom macroglobulinemia, obtain serum viscosity even if the IgM concentration appears only moderately elevated when visual or neurologic symptoms are present. [7][8]
- In suspected leukostasis, prioritize white blood cell count, blast evaluation, pulmonary and neurologic assessment, and immediate hematology-directed cytoreduction rather than plasma exchange as the primary intervention. [17][19]
- A patient with hyperviscosity symptoms and an atypical neurologic presentation in an IgM-associated malignancy may have a CNS complication such as Bing-Neel syndrome; do not attribute persistent neurologic findings solely to viscosity after plasma exchange. [16]

*Etiologic patterns that redirect emergency management. [5][16][17][18][19][23]*

| Pattern | Discriminators | Immediate management priority | Definitive direction |
| --- | --- | --- | --- |
| Waldenstrom macroglobulinemia | IgM-associated paraproteinemia with retinal, bleeding, or neurologic syndrome; most common paraprotein-associated setting [16][23] | Therapeutic plasma exchange for symptomatic hyperviscosity [18][23] | Concurrent hematology-directed cytoreductive therapy to prevent recurrence [18][23] |
| IgG or IgA myeloma | Monoclonal protein with myeloma features; symptomatic hyperviscosity is less frequent than in Waldenstrom macroglobulinemia [10][16] | Immediate plasmapheresis when symptomatic [18][24] | Myeloma-directed systemic therapy [18][24] |
| Cryoglobulinemia | Reversible serum gel formation with cooling and warming [5] | Plasmapheresis for rapidly evolving life-threatening disease [18] | Treat the causative cryoglobulinemic disorder [18] |
| Leukostasis | Symptomatic hyperleukocytosis, often with neurologic and pulmonary manifestations; white blood cell count generally greater than 100,000 cells/μL [17][19] | Isotonic fluids, emergency cytoreduction, tumor-lysis monitoring; limit red-cell transfusion unless symptomatic anemia requires it [17] | Acute leukemia-directed therapy [17][19] |

## Start plasma exchange promptly for symptomatic paraprotein hyperviscosity

Therapeutic plasma exchange is a bridge to clone-directed therapy, not definitive cancer control.

Initiate therapeutic plasma exchange as soon as possible for symptomatic paraprotein-mediated hyperviscosity. It rapidly lowers circulating paraprotein and can relieve clinical manifestations, including retinal microcirculatory compromise; early exchange may reduce blindness from retinal hemorrhage or retinal detachment. [18][23]

Use albumin replacement in routine exchanges: 4% to 5% human albumin in physiologic saline is commonly used. Consider fresh frozen plasma when a coagulation abnormality requires factor replacement. [18]

Repeat exchange based on persistent symptoms, retinal findings, and paraprotein burden rather than a single postprocedure number. In IgM-associated hyperviscosity, one to three daily procedures generally abate acute symptoms; IgG-associated hyperviscosity may require more procedures because removal is less efficient. [18]

Document response clinically after each procedure, with repeat retinal examination when ocular findings were present. Serum paraprotein measurement provides an objective adjunct, but acute treatment should be continued until the clinical syndrome abates. [18]
- Do not use plasma exchange as sole treatment: it does not eradicate the underlying malignancy and recurrence is expected without cytoreduction. [18][23]
- For active symptomatic hyperviscosity, begin disease-specific systemic treatment concurrently with plasma exchange under hematology direction. [18][23]
- In myeloma, bortezomib and carfilzomib are cited as agents that can rapidly reduce viscosity; in the appropriate hematologic context, ibrutinib is also cited as a rapidly acting cytoreductive option. Regimen selection depends on the underlying disease and hematology assessment. [23]

*Procedure-focused monitoring for paraprotein-mediated symptomatic hyperviscosity. [18][23]*

| Time point | Assess | Action |
| --- | --- | --- |
| Before first exchange | Bleeding, visual, neurologic, pulmonary, and heart-failure manifestations; serum viscosity and paraprotein burden when this does not delay treatment [18][23] | Arrange urgent therapeutic plasma exchange and start concurrent hematology-directed therapy. [18][23] |
| After each exchange | Symptoms, funduscopic findings when initially abnormal, and paraprotein level as an objective adjunct [18] | Continue daily exchange if acute manifestations persist. [18] |
| After symptom control | Evidence of recurrent visual, neurologic, or mucosal bleeding symptoms [3][18] | Maintain disease-directed therapy because plasma exchange alone does not prevent recurrence. [18][23] |

## Support microvascular perfusion while avoiding diagnosis-specific errors

Supportive interventions differ materially between paraprotein hyperviscosity and leukostasis.

Correct dehydration with crystalloid in suspected hyperviscosity because volume depletion increases viscosity and can worsen end-organ hypoperfusion. Monitor cardiopulmonary status closely in patients with dyspnea or heart failure manifestations, where fluid administration requires individualized balance. [16][23][24]

For leukostasis or marked hyperleukocytosis, use isotonic fluid resuscitation to reduce viscosity and maintain urine output while initiating emergency cytoreduction and tumor-lysis monitoring. Avoid diuretics unless clinically important volume overload is present. [17]

Avoid routine red-cell transfusion before leukocyte reduction in hyperleukocytosis because increasing hematocrit can increase blood viscosity and worsen leukostasis; reserve transfusion for symptomatic anemia. This caution is specific to the cellular hyperviscosity branch and should not delay treatment of clinically significant anemia when necessary. [17]
- Reassess neurologic deficits after viscosity reduction; persistent or focal findings require evaluation for competing CNS pathology, including CNS complications of IgM-associated disease. [16][20]
- Use both serum and whole-blood viscosity determinations when hyperviscosity-associated cognitive decline is suspected and the contribution of cellular versus serum factors is uncertain. [22]
- Do not use absence of a universal serum viscosity threshold to reassure a symptomatic patient; comorbid disease, including diabetic retinopathy, can lower the threshold for clinical manifestations. [1]

*Management distinctions that prevent treating the wrong viscosity syndrome. [17][18][23]*

| Decision | Paraprotein hyperviscosity | Leukostasis/hyperleukocytosis |
| --- | --- | --- |
| Primary emergency intervention | Therapeutic plasma exchange to remove circulating paraprotein [18][23] | Prompt cytoreductive chemotherapy; leukapheresis has an uncertain role in preventing complications or induction death in pediatric evidence summarized in review literature. [17] |
| Fluid strategy | Prompt crystalloid when dehydration is suspected [23] | Isotonic fluids to reduce viscosity and maintain urine output [17] |
| Red-cell transfusion | Individualize to clinical need | Limit until white blood cell count is reduced unless symptomatic anemia requires transfusion. [17] |
| Recurrence prevention | Disease-specific systemic therapy concurrent with exchange [18][23] | Definitive acute leukemia therapy and tumor-lysis prophylaxis/monitoring [17] |

## Common questions

### Should plasma exchange wait for a serum viscosity result?

No. In a patient with a compatible symptomatic paraprotein-associated syndrome, initiate urgent plasma exchange planning and treatment without waiting for the result; serum viscosity supports diagnosis and monitoring, but symptom thresholds vary. [1][18][23][24]

### How many plasma exchange procedures are usually required?

For IgM-associated hyperviscosity, one to three daily procedures generally relieve acute symptoms. IgG-associated disease may require more exchanges because immunoglobulin removal is less efficient; continue until acute manifestations abate. [18]

## References
1. Hyperviscosity Syndrome — www.bmj.com — https://www.bmj.com/content/bmj/2/5755/184.full.pdf
2. The Hyperviscosity Syndrome — jamanetwork.com — https://jamanetwork.com/HttpHandlers/ArticlePdfHandler.ashx?journal=JAMA&articleId=346991&pdfFileName=jama_236_4_034.pdf
3. Serum Hyperviscosity Syndrome — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/655524
4. With Hyperviscosity - Syndrome\p=m-\Response — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/578895/archinte_129_1_016.pdf?resultClick=1
5. Hyperviscosity syndrome caused by cryoglobulinemia ... — www.thelancet.com — https://www.thelancet.com/doi/story/10.1016/pic.2023.11.16.109674
6. Hyperviscosity Syndrome in a Patient With — archinte.jamanetwork.com — https://archinte.jamanetwork.com/data/Journals/INTEMED/17052/archinte_149_6_033.pdf
7. Hyperviscosity-Related Retinopathy in Waldenström ... — jamanetwork.com — https://jamanetwork.com/journals/jamaophthalmology/fullarticle/418701
8. Waldenstrom macroglobulinemia: prognosis and ... — www.nature.com — https://www.nature.com/articles/bcj201528
9. Exploring effects of platelet contractility on the kinetics ... — www.nature.com — https://www.nature.com/articles/s44341-025-00011-9
10. Rheological properties of blood in multiple myeloma patients | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-54947-4
11. Bilateral simultaneous central retinal vein occlusion ... — www.nature.com — https://www.nature.com/articles/eye2008193
12. Management of macroglobulinaemia — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/bjh.14742
13. Efficacy and safety of therapeutic procedure for ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/1744-9987.14094
14. Waldenström Macroglobulinemia: 2025 Update on ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27666
15. Waldenström macroglobulinemia: 2023 update on ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.26796
16. Hyperviscosity Syndrome - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/hyperviscosity-syndrome
17. Leukostasis - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/leukostasis
18. The use of emergency apheresis in the management of plasma cell disorders — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S147305021830048X
19. Rapid Fire: Acute Blast Crisis/Hyperviscosity Syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0733862718300282
20. Primary CNS Lymphoma and Neurologic Complications of ... — journals.lww.com — https://journals.lww.com/continuum/fulltext/2015/04000/primary_cns_lymphoma_and_neurologic_complications.10.aspx
21. Effect of Plasmapheresis on Hyperviscosity-Related ... - IOVS — iovs.arvojournals.org — https://iovs.arvojournals.org/article.aspx?articleid=2184720
22. Hyperviscosity‐induced dementia — www.neurology.org — https://www.neurology.org/doi/10.1212/WNL.33.1.101
23. Hyperviscosity Syndrome | Critical Care Medicine Section — www.acep.org — https://www.acep.org/criticalcare/newsroom/newsroom-articles/january-2025/hyperviscosity-syndrome
24. Multiple Myeloma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK534764

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.